Post Authorisation Safety Study With Raxone in LHON Patients
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
This study is a multicentre, prospective, non-interventional post-authorisation safety study
(PASS) of the clinical outcomes for patients with LHON treated with Raxone®.
No medication will be provided as part of this study. Raxone® will be obtained through
commercial channels.